Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 5,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent Clear all

Conditions: Heart Failure, Systolic, Frailty
Interventions: sacubitril/valsartan, Angiotensin II Receptor Blockers; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 65 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma, Primary Open Angle, Cataract
Interventions: Intracanalicular Dexamethasone, 0.4 mg insert; Drug
Lead sponsor: Wolstan and Goldberg Eye Associates; Network
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Torrance, California

Conditions: Opioid Use Disorder, Opioid Use, Opioid Abuse, Opioid Misuse, Opioid Dependence
Interventions: buprenorphine/naloxone; Drug
Lead sponsor: Bicycle Health; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Essential Oil Blend (Botanical Combination Product), Placebo; Other
Lead sponsor: dōTERRA International; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Pleasant Grove, Utah

Conditions: Heart Disease, Blocked Arteries, Coronary Ischemia, Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis
Interventions: MESENDO, placebo; Biological · Other
Lead sponsor: TCA Cellular Therapy; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Covington, Louisiana

Conditions: Solid Tumors, Lung Cancer
Interventions: BKM120, Everolimus; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Heart Failure
Interventions: LCZ 696, Icatibant, placebo, Para-aminohippurate, Iohexol; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Small Cell Lung Cancer
Interventions: Alisertib, Placebo, Paclitaxel; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 21
States / cities: Los Angeles, California • Sacramento, California • New Haven, Connecticut + 18 more

Conditions: HIV Infections
Interventions: Saquinavir, Nevirapine, Zidovudine, Zalcitabine; Drug
Lead sponsor: Parexel; Industry
Eligibility: 13 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Osteoarthritis (OA) of the Knee
Interventions: Periarticular Injection, Adductor Canal Block, Bupivacaine-Meloxicam; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Grosse Pointe Farms, Michigan

Conditions: Tobacco Use
Interventions: e-cigarette, Nicotine patch, Nicotine lozenge; Behavioral · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Depressive Disorder
Interventions: Carbidopa/levodopa, Placebo, Exercise training, Control; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 60 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: Abilify MyCite®; Combination Product
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 68
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 55 more

Conditions: Meningitis, Cryptococcal, HIV Infections
Interventions: Fluconazole, Amphotericin B; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 7
States / cities: San Francisco, California • Wilmington, Delaware • Tampa, Florida + 4 more

Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
Interventions: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more

Conditions: Colorectal Cancer
Interventions: chemotherapy, computed tomography, conventional surgery, neoadjuvant therapy, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis Vulgaris
Interventions: 0.01% Halobetasol, 0.045% Tazarotene, 0.05% Clobetasol Propionate; Drug
Lead sponsor: Dermatology Consulting Services, PLLC; Network
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Medical Oncology
Interventions: BAY1217389, Paclitaxel; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 6
States / cities: Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 27
States / cities: Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more

Conditions: Intra Abdominal Infections
Interventions: Ertapenem, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin, Metronidazole, Amoxicillin-Clavulanate, Sulopenem; Drug
Lead sponsor: Iterum Therapeutics, International Limited; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 12
States / cities: Chula Vista, California • Torrance, California • Idaho Falls, Idaho + 8 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: repaglinide, metformin, repaglinide and metformin combination tablet; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infections
Interventions: Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate, Efavirenz; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 5
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Manhasset, New York + 2 more

Conditions: Epithelial Ovarian Cancer
Interventions: Torvutatug samrotecan, Bevacizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 6
States / cities: Tamarac, Florida • Tampa, Florida • Baton Rouge, Louisiana + 3 more

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 62
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 55 more

Search by objective public record fields.

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert

Novel Induction to Buprenorphine/Naloxone

Efficacy and Safety of an Essential Oil-Based Product System for Immune Support

Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection

Novel Extended-Release Bupivacaine Polymer for Sustained Pain Relief Following Total Knee Arthroplasty

Quit or Switch: E-cigarette Study

Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing

A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

PET and CT Scans in Patients With Locally Advanced Primary Rectal Cancer That Can Be Removed During Surgery

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation